fda glp-1 compounding enforcement october 2025 Dr. Elizabeth Kazarian, MD | Evidence based doctors never prescribed compounded GLP1. The rest of you are catching up. Feb 6 2026 : “Today, the U.S. Food and Drug FDA Sends Warning Letters to

They may help lower risk of cardiovascular disease and diabetes.

Discover Nico's personalized GLP-1 weight management programs featuring compounded medications prescribed by licensed healthcare providers and prepared by state-licensed pharmacies.

So you can rule your day

However, not all patients can access GLP-1s at the same pace

Implementation of GLP-1 RA-specific medical nutrition therapy protocols, with dietitian involvement to optimize dietary recommendations and manage adverse events, is recommended

Show Segments 00:03- Introduction 01:19- Exploring GLP-1RA in the News 02:49- Scientific Background of GLP-1 RA 05:38- Current Research on Semaglutide 07:13- Study Design and Methodology 10:38- Potential Applications of GLP-1RA Beyond Alcohol Use Disorder 12:15- Challenges in Integrating GLP-1RA into Addiction Care 15:16- Practical Steps for Addiction Care Providers 18:19 Looking to the Future 19:27 Conclusion and Additional Learning Opportunities Key Takeaways Semaglutide, a GLP-1RA, is currently being studied as a potential adjunctive therapy for alcohol use disorder